GlassScriptPhysician profile
Ashley D Bell
NPI 1114562782
$22,254.23
in general payments reported to CMS, 2019-2025
73 companies · $4,636 in 2025
The $4,636 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,956 · 2022: $4,653 · 2023: $4,466 · 2024: $4,543 · 2025: $4,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $1,280 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,965.78 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $399.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,385.38 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,395.92 | 2021-2025 | Enhertu, Tagrisso, Calquence |
| Incyte Corporation | $1,206.28 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $1,164.17 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $1,119.38 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $1,036.43 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $978.70 | 2021-2025 | |
| Celgene Corporation | $848.29 | 2021-2025 | Reblozyl, Breyanzi, Opdivo |
| Merck Sharp & Dohme LLC | $775.07 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $764.05 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $713.12 | 2021-2025 | Phesgo, Venclexta, Perjeta |
| Genzyme Corporation | $618.02 | 2021-2025 | |
| Astellas Pharma US INC | $599.15 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Lilly USA, LLC | $577.59 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $499.99 | 2021-2025 | Jemperli, Ojjaara, Zejula |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $466.22 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.16 | 2021-2025 | Ninlaro, Alunbrig |
| Gilead Sciences, INC. | $414.78 | 2021-2025 | Trodelvy |
| Eisai INC. | $414.63 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $338.60 | 2021-2024 | Myrisk, Precisetumor |
| Amgen INC. | $335.23 | 2022-2023 | Kyprolis, Lumakras, Nplate |
| Exelixis INC. | $326.16 | 2021-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $280.40 | 2021-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $274.65 | 2021-2024 | Brukinsa |
| Abbvie INC. | $273.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.17 | 2021-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $238.85 | 2022-2025 | Fotivda |
| Alexion Pharmaceuticals, INC. | $206.68 | 2021-2024 | Ultomiris |
| Array Biopharma INC | $205.86 | 2021-2025 | Braftovi, Mektovi, Xalkori |
| Sobi, INC | $193.21 | 2022-2025 | |
| Mirati Therapeutics, INC. | $185.61 | 2023 | Krazati |
| Emd Serono, INC. | $175.36 | 2021-2025 | Bavencio |
| Karyopharm Therapeutics INC. | $173.52 | 2021-2025 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $160.82 | 2021-2025 | Onivyde |
| Rigel Pharmaceuticals, INC. | $147.07 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Morphosys, US INC. | $143.90 | 2022-2024 | Monjuvi |
| Tersera Therapeutics LLC | $142.26 | 2021-2024 | Zoladex |
| Pharmacosmos Therapeutics INC. | $124.82 | 2021-2025 | Monoferric |
| Taiho Oncology, INC. | $117.65 | 2023-2025 | |
| G1 Therapeutics, INC. | $101.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Coherus Oncology, INC. | $88.70 | 2021-2022 | |
| Stemline Therapeutics INC. | $88.01 | 2022-2023 | Orserdu, Elzonris |
| Pharmaessentia USA Corporation | $86.90 | 2022-2025 | Besremi |
| Beone Medicines USA, INC. | $81.47 | 2025 | Tevimbra, Brukinsa |
| Springworks Therapeutics, INC. | $79.26 | 2024-2025 | Ogsiveo |
| Puma Biotechnology, INC. | $75.22 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.82 | 2021-2024 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $71.39 | 2023-2025 | Qinlock, Romvimza |
| Tg Therapeutics, INC. | $60.88 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $56.00 | 2021-2022 | |
| Blueprint Medicines Corporation | $46.53 | 2021-2024 | Ayvakit |
| Acrotech Biopharma INC. | $43.11 | 2021 | |
| Epizyme, INC. | $40.62 | 2021-2022 | |
| Genmab U.S., INC. | $40.57 | 2024-2025 | Epkinly |
| Legend Biotech USA INC. | $38.20 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $36.86 | 2023-2024 | Empaveli |
| Novocure INC. | $35.66 | 2025 | Optune Lua (Novottf-200t) |
| Clovis Oncology, INC. | $33.46 | 2021 | |
| Acceleron Pharma, INC. | $32.88 | 2021 | |
| Myovant Sciences INC. | $30.19 | 2022 | |
| Iovance Biotherapeutics, INC. | $26.15 | 2025 | Amtagvi |
| Servier Pharmaceuticals LLC | $23.04 | 2024 | |
| Kite Pharma, INC. | $22.85 | 2025 | Yescarta |
| Azurity Pharmaceuticals, INC. | $19.91 | 2025 | Vivimusta, Danziten |
| Caris Mpi, INC. | $19.46 | 2025 | Mi Cancer Seek |
| Nuvation Bio INC. | $19.18 | 2025 | Ibtrozi |
| Verity Pharmaceuticals INC. | $15.24 | 2023 | Trelstar |
| Heron Therapeutics, INC. | $14.72 | 2021 | |
| Kyowa Kirin, INC. | $12.31 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.85 | 2021 | |
| Secura Bio, INC. | $7.30 | 2022 | |
| Organon LLC | $6.27 | 2023 |
Drugs and devices associated with these payments
Kisqali $1,687Enhertu $851Jakafi $497Reblozyl $479Verzenio $397Jaypirca $377Opdivo $372Xtandi $309Imbruvica $297Keytruda $294Retevmo $290Padcev $290Nubeqa $255Opdualag $249Tagrisso $247Tecvayli $239Xofigo $235Krazati $230Tukysa $226Venclexta $222Monjuvi $213Cabometyx $213Darzalex $212Ibrance $198Myrisk $192Talzenna $189Stivarga $176Fotivda $175Fabhalta $172Libtayo $170Orgovyx $162Jemperli $156Sarclisa $150Ninlaro $143Lorbrena $134Phesgo $131Talvey $130Epkinly $130Vitrakvi $124Braftovi $121Mektovi $121Scemblix $119Lonsurf $118Inqovi $118Elrexfio $117Xalkori $113Lenvima $112Calquence $110Welireg $107Zynyz $107Ojjaara $106Brukinsa $104Xpovio $101Trodelvy $101Adcetris $99.83Rybrevant $99.31Perjeta $94.96Promacta $94.54Onivyde $94.11Inlyta $91.25Lutathera $88.61Carvykti $85.20Enjaymo $83.62Zejula $80.37Zoladex $79.95Ogsiveo $79.26Pemazyre $74.87Bavencio $74.33Vyloy $71.98Monoferric $71.59Qinlock $71.39Bosulif $69.87Besremi $68.64Pluvicto $65.93Vonjo $64.32Datroway $60.64Tecentriq $59.96Cablivi $58.00Romvimza $52.88Orserdu $51.67Ultomiris $50.61Comirnaty $49.06Tevimbra $47.90Lynparza $46.55Erleada $46.53Balversa $46.53Breyanzi $45.26Alunbrig $44.48Polivy $42.62Lunsumio $42.62Doptelet $42.54Kyprolis $42.28Tavalisse $41.88Rezlidhia $41.88Alecensa $39.83Empaveli $36.86Optune Lua (Novottf-200t) $35.66Precisetumor $34.08Paxlovid $34.05Lumakras $33.12
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.